1. Home
  2. AHH vs ABUS Comparison

AHH vs ABUS Comparison

Compare AHH & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AHH
  • ABUS
  • Stock Information
  • Founded
  • AHH 1979
  • ABUS 2005
  • Country
  • AHH United States
  • ABUS United States
  • Employees
  • AHH N/A
  • ABUS N/A
  • Industry
  • AHH Real Estate
  • ABUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • AHH Finance
  • ABUS Health Care
  • Exchange
  • AHH Nasdaq
  • ABUS Nasdaq
  • Market Cap
  • AHH 599.4M
  • ABUS 672.1M
  • IPO Year
  • AHH 2013
  • ABUS N/A
  • Fundamental
  • Price
  • AHH $6.82
  • ABUS $3.15
  • Analyst Decision
  • AHH Buy
  • ABUS Strong Buy
  • Analyst Count
  • AHH 3
  • ABUS 4
  • Target Price
  • AHH $9.83
  • ABUS $5.50
  • AVG Volume (30 Days)
  • AHH 874.6K
  • ABUS 832.7K
  • Earning Date
  • AHH 05-07-2025
  • ABUS 05-14-2025
  • Dividend Yield
  • AHH 11.07%
  • ABUS N/A
  • EPS Growth
  • AHH 9.49
  • ABUS N/A
  • EPS
  • AHH 0.10
  • ABUS N/A
  • Revenue
  • AHH $627,963,000.00
  • ABUS $6,403,000.00
  • Revenue This Year
  • AHH N/A
  • ABUS $14.57
  • Revenue Next Year
  • AHH $2.00
  • ABUS $15.84
  • P/E Ratio
  • AHH $70.69
  • ABUS N/A
  • Revenue Growth
  • AHH N/A
  • ABUS N/A
  • 52 Week Low
  • AHH $6.10
  • ABUS $2.71
  • 52 Week High
  • AHH $12.46
  • ABUS $4.73
  • Technical
  • Relative Strength Index (RSI)
  • AHH 41.34
  • ABUS 46.05
  • Support Level
  • AHH $6.65
  • ABUS $3.04
  • Resistance Level
  • AHH $7.43
  • ABUS $3.42
  • Average True Range (ATR)
  • AHH 0.20
  • ABUS 0.17
  • MACD
  • AHH 0.04
  • ABUS -0.02
  • Stochastic Oscillator
  • AHH 22.31
  • ABUS 31.01

About AHH Armada Hoffler Properties Inc.

Armada Hoffler Properties Inc is a real estate company. It engages in developing, building, owning and managing the high-quality, institutional-grade office, retail, and multifamily properties in various markets throughout the Mid-Atlantic and Southeastern United States. It lease its properties under operating leases and recognize base rents. It also recognize revenue from tenant recoveries, through which tenants reimburses the company for expenses paid by them such as utilities, janitorial, repairs and maintenance. The company's operating segment includes office real estate, retail real estate, multifamily residential real estate, and general contracting, real estate financing and real estate services. It generates maximum revenue from the retail real estate segment.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: